Correlation Engine 2.0
Clear Search sequence regions


  • humans (1)
  • life expectancy (1)
  • octogenarian (4)
  • patients (9)
  • scale (3)
  • stroke (3)
  • ticagrelor (4)
  • Sizes of these terms reflect their relevance to your search.

    There has been an increase in the number of percutaneous coronary intervention (PCI) procedures performed in octogenarian patients due to increased life expectancy and developments in modern medicine. Frailty is associated with the aging process, gradual loss of multiple body functions, and poor health outcomes. We examined the association between frailty and major bleeding in octogenarian patients undergoing PCI. We retrospectively analyzed the records of two local research hospitals in Turkey. In total, 244 patients were enrolled in this study. Patients were divided into two groups based on their Clinical Frailty Scale (CFS) score. The non-frail group included patients with CFS scores of 1 (very fit) to 4 (living with very mild frailty), while the frail group included those with CFS scores of 5 (living with mild frailty) to 9 (terminally ill). Of the 244 patients, 131 were classified into the non-frail group and 113 into the frail group. Ticagrelor use was significantly more common in the non-frail group (31.3% vs. 20.4%, p=0.036). Major bleeding was more common in the frail than non-frail group (20.4% vs. 6.1%, p<0.001). The rates of stroke and all-cause death were higher in the frail than in non-frail group (stroke 15.9% vs. 3.8%, p<0.001, as well as all-cause mortality rate (27.4% vs. 2.3%, p<0.001). Frailty is an independent predictor of major bleeding in patients undergoing PCI for acute coronary syndrome. Use of the P2Y12 inhibitor ticagrelor increases the risk of major bleeding in frail patients.

    Citation

    K Özbek, A Balun. Effect of frailty on major bleeding in octogenarian patients undergoing percutaneous coronary intervention. European review for medical and pharmacological sciences. 2023 Jun;27(11):5159-5166

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37318490

    View Full Text